A Pilot, Randomised, Blinded, Feasibility, Safety and Biochemical and Physiological Efficacy Study of Terlipressin versus Placebo in Hypotensive Sepsis

Phase 4

Recruiting

• Conditions: Hospitalised patients with sepsis-associated hypotension; Infection - Other infectious diseases; Cardiovascular - Other cardiovascular diseases

• Registration Number: ACTRN12613001191785
• Lead Sponsor: Anaesthesia Intensive Care Trust Fund

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-10-30
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Patients aged 18 years or older
- Confirmed or suspected sepsis
presentation to the emergency department (ED) or activation of an urgent medical emergency team review or admission to the intensive care unit
Hypotension

Exclusion Criteria

- Pregnancy
- Death is considered imminent (within 24 hours)
- Known contraindications to terlipressin such as: severe peripheral vascular disease, Raynaud's phenomenon, Known allergy to terlipressin, Unstable angina, Recent myocardial infarction, Asthma.

Study & Design

• Study Type: Interventional
• Study Design: Not specified